Cancer Panel

Summary and Pricing

Test Method

Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture Probes
Test Code Test Copy GenesCPT Code Copy CPT Codes
5471 AIP 81479,81479 Add to Order
ALK 81479,81479
ANKRD26 81479,81479
APC 81201,81203
ARMC5 81479,81479
ATM 81408,81479
AXIN2 81479,81479
BAP1 81479,81479
BARD1 81479,81479
BLM 81479,81479
BMPR1A 81479,81479
BRCA1 and BRCA2 81162
BRIP1 81479,81479
CDC73 81479,81479
CDH1 81406,81479
CDK4 81479,81479
CDKN1B 81479,81479
CDKN1C 81479,81479
CDKN2A 81404,81479
CEBPA 81218,81479
CHEK2 81479,81479
DDX41 81479,81479
DICER1 81479,81479
DIS3L2 81479,81479
EPCAM 81479,81403
ETV6 81479,81479
EXT1 81479,81479
EXT2 81479,81479
FANCC 81479,81479
FH 81405,81479
FLCN 81479,81479
GALNT12 81479,81479
GATA2 81479,81479
GPC3 81479,81479
GREM1 81479,81479
HOXB13 81479,81479
HRAS 81404,81479
KIF1B 81479,81479
KIT 81479,81479
LZTR1 81479,81479
MAX 81479,81479
MEN1 81405,81404
MET 81479,81479
MITF 81479,81479
MLH1 81292,81294
MLH3 81479,81479
MRE11 81479,81479
MSH2 81295,81297
MSH3 81479,81479
MSH6 81298,81300
MUTYH 81406,81479
NBN 81479,81479
NF1 81408,81479
NF2 81406,81405
NTHL1 81479,81479
PALB2 81406,81479
PALLD 81479,81479
PDGFRA 81479,81479
PHOX2B 81404,81403
PMS2 81317,81319
POLD1 81479,81479
POLE 81479,81479
POT1 81479,81479
PRKAR1A 81479,81479
PTCH1 81479,81479
PTCH2 81479,81479
PTEN 81321,81323
RAD50 81479,81479
RAD51C 81479,81479
RAD51D 81479,81479
RB1 81479,81479
RECQL 81479,81479
REST 81479,81479
RET 81406,81479
RUNX1 81479,81479
SAMD9L 81479,81479
SDHA 81406,81479
SDHAF2 81479,81479
SDHB 81405,81479
SDHC 81405,81404
SDHD 81404,81479
SMAD4 81406,81405
SMARCA4 81479,81479
SMARCB1 81479,81479
SMARCE1 81479,81479
SRP72 81479,81479
STK11 81405,81404
SUFU 81479,81479
TERC 81479,81479
TERT 81479,81479
TMEM127 81479,81479
TP53 81405,81479
TRIP13 81479,81479
TSC1 81406,81405
TSC2 81407,81406
VHL 81404,81403
WT1 81405,81479
XRCC2 81479,81479
Full Panel Price* $690
Test Code Test Copy Genes Total Price CPT Codes Copy CPT Codes
5471 Genes x (99) $690 81162, 81201, 81203, 81218, 81292, 81294, 81295, 81297, 81298, 81300, 81317, 81319, 81321, 81323, 81403(x3), 81404(x8), 81405(x10), 81406(x9), 81407, 81408(x2), 81479(x148) Add to Order

Pricing Comments

We are happy to accommodate requests for testing single genes in this panel or a subset of these genes. The price will remain the list price. If desired, free reflex testing to remaining genes on panel is available.

This test is also offered via our exome backbone with CNV detection (click here). The exome-based test may be higher priced, but permits reflex to the entire exome or to any other set of clinically relevant genes.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.

Turnaround Time

The great majority of tests are completed within 20 days.

EMAIL CONTACTS

Genetic Counselors

Geneticist

Clinical Features and Genetics

Clinical Features

Hereditary cancer syndromes have been observed in approximately 5-10% of diagnosed cancers (Mauer et al. 2013. PubMed ID: 24113346). Hereditary cancers tend to occur at an earlier age (<50 years), tumors often occur bilaterally and/or are multifocal, consist of multiple affected family members, may include a less frequently affected gender (breast cancer in males), can be associated with other clinical features, and occur with a higher predisposition in specific ethnicities, such as the Ashkenazi Jewish population (Lindor et al. 2008. PubMed ID: 18559331). The results of testing for a group of hereditary cancers can be important for counseling, screening and treatment (O’Daniel and Lee. 2012. PubMed ID: 22846728; Imyanitov and Byrski. 2013. PubMed ID: 23548133). Additionally, assessment of multiple genes associated with hereditary cancers can be useful in determining personal or familial risks (Foulkes. 2008. PubMed ID: 19005198).

Genetics

This test analyzes genes involved in multiple hereditary cancer syndromes which are mostly inherited in an autosomal dominant manner. Several types of cancers may be found in a pedigree and this test may help in the differential diagnosis and rule out particular syndromes by simultaneously analyzing multiple genes involved in hereditary cancers.

Phenotype clusters from this panel include: Breast Cancer, Colorectal Cancer, Endocrine Cancer, Endometrial Cancer, Gastric Cancer, Melanoma Predisposition, Neurological Tumors, Ovarian Cancer, Pancreatic Cancer, Paraganglioma and Pheochromocytoma, Pediatric Cancer, Polyposis, Prostate Cancer, Renal Cancer, Sarcoma, and Thyroid Cancer.

See individual gene test descriptions for detailed information on clinical features, molecular biology of gene products, and spectra of pathogenic variants.

Testing Strategy

For this Next Generation Sequencing (NGS) test, sequencing is accomplished by capturing specific regions with an optimized solution-based hybridization kit, followed by massively parallel sequencing of the captured DNA fragments.

For Sanger sequencing, polymerase chain reaction (PCR) is used to amplify targeted regions. After purification of the PCR products, cycle sequencing is carried out using the ABI Big Dye Terminator v.3.0 kit. PCR products are resolved by electrophoresis on an ABI 3730xl capillary sequencer. In nearly all cases, cycle sequencing is performed separately in both the forward and reverse directions.

Copy number variants (CNVs) are also detected from NGS data. We utilize a CNV calling algorithm that compares mean read depth and distribution for each target in the test sample against multiple matched controls. Neighboring target read depth and distribution and zygosity of any variants within each target region are used to reinforce CNV calls. All CNVs are confirmed using another technology such as aCGH, MLPA, or PCR before they are reported.

This panel typically provides ≥98% coverage of all coding exons of the genes listed, plus ~10 bases of flanking noncoding DNA. We define coverage as ≥20X NGS reads or Sanger sequencing.

The PHOX2B exon 3 polyalanine region is not covered.

This panel also includes testing for the inversion of exons 1-7 in MSH2.

Deletion and duplication testing for STK11, NF1, and PMS2 is performed using NGS, but CNVs detected in these genes are confirmed via multiplex ligation-dependent probe amplification (MLPA).

Clinical Sensitivity - Sequencing and CNV

Genes tested in this panel have been implicated in hereditary cancer, and although individually these genes may be involved in a minority of cancers, the combination of highly, moderately, and mildly penetrant pathogenic variants may be responsible for a significant portion of hereditary cancers.

Clinical sensitivity for this panel is highly dependent on the type of cancer, specific ethnicity, and age of patients.

One study of 227 individuals with a personal or family history of cancer undergoing multigene panel testing found that 12% of individuals had a pathogenic variant and 29.5% had a variant of uncertain significance (Hermel et al. 2017. PubMed ID: 27401692). Approximately 13% of cases had changes in medical care due to panel testing results.

Another study of 10,000 patients with various cancers referred for multigene panel testing found a molecular diagnosis in 9% of patients tested (Susswein et al. 2016. PubMed ID: 26681312). Positive rates were found in 9.7%, 13.4%, and 14.8% for patients with breast, ovarian, or colon/stomach cancer, respectively.

Clinical sensitivity of commonly tested genes is given based on each disorder.

CHEK2-related Cancers: Pathogenic CHEK2 sequence variants are reported in hereditary breast cancer and have been reported in 4.5% of cases (Castéra et al. 2014. PubMed ID: 24549055).

Familial Adenomatous Polyposis (FAP): Pathogenic APC sequence variants are found in >90% of individuals with FAP (Laken et al. 1999. PubMed ID: 10051640). Gross deletions/duplications have been reported in up to 12% of APC patients (Jasperson et al. 2017. PubMed ID: 20301519).

Hereditary Breast and Ovarian Cancer (HBOC): The overall prevalence of germline BRCA1 or BRCA2 pathogenic variants in the general population is 1:400 to 1:800, with higher rates depending on the specific ethnicity, such as 1:40 in the Ashkenazi Jewish population. Nucleotide substitutions and small insertions or deletions are found in about 90% of individuals with an identifiable pathogenic variant. For individuals with pathogenic variants in these genes, BRCA1 variants were observed in 63% and BRCA2 variants in 37% (Petrucelli et al. 2016. PubMed ID: 20301425). Copy number variants (CNVs) are found in approximately 10% of individuals with an identifiable BRCA1/2 germline pathogenic variant, with 90% of these in BRCA1 and 10% in BRCA2 (Petrucelli et al. 2016. PubMed ID: 20301425).

A study by Walsh et al (2011) found approximately 6% of patients with hereditary ovarian cancers who do not have pathogenic variants in BRCA1 or BRCA2 have pathogenic variants in genes such as BARD1, BRIP1, CHEK2, MRE11, NBN, PALB2, RAD50, RAD51C, and TP53 (Walsh et al. 2011. PubMed ID: 22006311). Another study by Castéra et al. found that around a third of the deleterious variants they identified in their patient cohort were in genes outside of BRCA1/2, including CDH1, CHEK2, PALB2, and TP53 (Castéra et al. 2014. PubMed ID: 24549055). HBOC associated gross deletions have been reported for the RAD51C (Vuorela et al. 2011. PubMed ID: 21750962), PALB2 (Antoniou et al. 2014. PubMed ID: 25099575), and TP53 (Melhem-Bertrandt et al. 2012. PubMed ID: 21761402) genes.

Hereditary Diffuse Gastric Cancer (HDGC): The clinical sensitivity of pathogenic CDH1 sequence variants is 30% for HDGC families (Carneiro et al. 2007. PubMed ID: 17513507). Large deletions have been detected in the CDH1 gene in up to 4% of patients (Kaurah and Huntsman. 2014. PubMed ID: 20301318).

Hereditary Paraganglioma-Pheochromocytoma Syndrome: Although the majority of hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome tumors are sporadic (non-familial), approximately 13% of all PGL/PCC tumors are caused by germline pathogenic variants in known PGL/PCC syndrome genes (Welander et al. 2011. PubMed ID: 22041710).

Juvenile Polyposis Syndrome (JPS): This test is predicted to identify a pathogenic BMPR1A sequence variant in 11-22% and a pathogenic SMAD4 sequence variant in 20-26% of patients diagnosed with JPS. Deletion/duplication analysis is predicted to identify a BMPR1A pathogenic variant in 1-2% and a SMAD4 pathogenic variant in 2-9% of patients diagnosed with JPS (Larsen Haidle and Howe. 2017. PubMed ID: 20301642).

Li-Fraumeni Syndrome: Sequencing the TP53 gene can detect approximately 95% of patients with Li-Fraumeni syndrome. Deletions in the TP53 gene have been detected in 1% of Li-Fraumeni cases (Schneider et al. 2013. PubMed ID: 20301488).

Lynch Syndrome: Depending on the clinical criteria used to make a diagnosis (Amsterdam or “Revised Bethesda”), 30-50% and 15-20% of Lynch patients have a detectable pathogenic MLH1 and MSH2 sequence variant, respectively (Syngal et al. 2000. PubMed ID: 10978352). A pathogenic sequence variant in MSH6 is detected in <2% of patients that meet the stringent Amsterdam I criteria but is detected in ~12% of atypical Lynch/HNPCC families (Peltomäki and Vasen 2004. PubMed ID: 15528792). A pathogenic PMS2 sequence variant is detected in 1-2% of Lynch patients (Peltomäki and Vasen 2004. PubMed ID: 15528792) and ~50% of constitutional mismatch repair-deficiency patients (Wimmer and Etzler. 2008. PubMed ID: 18709565). The clinical sensitivity of EPCAM sequence variants in Lynch syndrome is unknown as no pathogenic sequence variants have been reported for this disease; however, sequence variants in the EPCAM gene are known to be causative for congenital tufting enteropathy. The clinical sensitivity of EPCAM deletions is 1-3% of individuals with Lynch Syndrome (Kohlmann and Gruber. 2018. PubMed ID: 20301390). Lynch syndrome is attributed to deletions in the MLH1, MSH2, MSH6, and PMS2 genes in approximately 5%, 20%, 7%, and 20% of cases, respectively (Kohlmann and Gruber. 2018. PubMed ID: 20301390).

Melanoma: 25-50% of familial melanoma cases have causative germline variants in CDKN2A, and there is a 1-3% chance that an individual with primary melanoma has a causative germline variant in CDKN2A (Nelson and Tsao. 2009. PubMed ID: 19095153; Ibrahim et al. 2009. PubMed ID: 19400696). Only 2% of the families in the Geno-MEL study carried CDK4 pathogenic variants (Goldstein et al. 2006. PubMed ID: 17047042). Clinical sensitivity for CDKN2A and CDK4 deletions/duplications is not currently known.

Multiple Endocrine Neoplasia type 2 and Familial Medullary Thyroid Carcinoma: This test is predicted to detect pathogenic variants in >95% of cases (Marquard and Eng. 2015. PubMed ID: 20301434).

MUTYH-Associated Polyposis: By definition, nearly all (~99%) MAP patients have biallelic germline pathogenic variants in MUTYH. However, pathogenic variants in MUTYH are also found in ~25% of patients initially diagnosed with familial adenomatous polyposis (FAP) (Sampson et al. 2003. PubMed ID: 12853198). Clinical sensitivity for MUTYH deletions/duplications is not currently known.

Pancreatic Cancer Pathogenic ATM heterozygous variants in familial pancreatic cancer can be observed in up to 5% individuals (Bartsch et al. 2012. PubMed ID: 22664588; Solomon et al. 2012. PubMed ID: 23187834). Pathogenic variants in BRCA1, BRCA2, and CDKN2A have recently been reported in 1.2%, 3.7%, and 2.5% of individuals, respectively, in a study of familial pancreatic cancer (Zhen et al. 2015. PubMed ID: 25356972). One large study showed that 21% of individuals or families with Lynch syndrome had at least one case of pancreatic cancer (Kastrinos et al. 2009. PubMed ID: 19861671).

Peutz-Jeghers Syndrome: Approximately 55% of patients with a positive family history or 70% of patients with no family history of Peutz-Jeghers syndrome will be detected by STK11 sequencing. Approximately 45% of patients with a positive family history or 21% of patients with no family history of Peutz-Jeghers syndrome will have a pathogenic variant in STK11 by deletion analysis (McGarrity et al. 2016. PubMed ID: 20301443).

POLD1 and POLE Colorectal Cancer Predisposition: Pathogenic sequence variants in the POLD1 and POLE genes have been observed in 0.2% and 0.3-0.6% of individuals with colorectal cancer, respectively (Chubb et al. 2015. PubMed ID: 25559809).

Prostate Cancer: In a recent study of 692 men with documented metastatic prostate cancer, pathogenic variants in these genes were identified, including ATM (11 pathogenic variants [13% of total]), BRCA1 (6 [7%]), BRCA2 (37 [44%]), CHEK2 (10 [12%]), and PALB2 (3 [4%]) (Pritchard et al. 2016. PubMed ID: 27433846).

PTEN Hamartoma Syndrome: This test is predicted to detect causative PTEN pathogenic variants in ~80% of patients with Cowden syndrome (CS), ~65% of patients with Bannayan-Riley-Ruvalcaba syndrome (BRRS) and ~20% of patients with Proteus syndrome (PS). Large deletions are predicted to be detected in ~11% of patients with BRRS, but the sensitivity is not known for other PTEN related disorders (Eng 2003. PubMed ID: 12938083).

Indications for Test

Individuals with a clinical presentation of a cancer syndrome or a family history of cancer are candidates. Clinical presentation or family history includes early-onset cancer, multiple primary cancers, multiple family members with cancer, and individuals of Ashkenazi descent with a concern for cancer. Earlier detection of tumors will often lead to better outcomes. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.

Diseases

Name Inheritance OMIM ID
Adenomatous Polyposis Coli AD 175100
Aml - Acute Myeloid Leukemia AD 601626
Ataxia-Pancytopenia Syndrome AD 159550
Ataxia-Telangiectasia-Like Disorder AR 604391
Atrial Myxoma, Familial AD 255960
Bannayan-Riley-Ruvalcaba Syndrome AD 153480
Beckwith-Wiedemann Syndrome AD 130650
Birt-Hogg-Dube Syndrome AD 135150
Bloom Syndrome AR 210900
Bone Marrow Failure Syndrome 1 AD 614675
Breast-Ovarian Cancer, Familial 1 AD 604370
Breast-Ovarian Cancer, Familial 2 AD 612555
Breast-Ovarian Cancer, Familial 4 AD 614291
Carney Complex, Type 1 AD 160980
Colorectal Cancer 1 AD 608812
Colorectal cancer, susceptibility to, 10 AD 612591
Colorectal cancer, susceptibility to, 12 AD 615083
Costello Syndrome AD 218040
Cowden Disease AD 158350
Cutaneous Malignant Melanoma 1 AD 155600
Exostoses, Multiple, Type I AD 133700
Exostoses, Multiple, Type II AD 133701
Familial Adenomatous Polyposis 3 AR 616415
Familial Adenomatous Polyposis 4 AR 617100
Familial Cancer Of Breast AD 114480
Familial Medullary Thyroid Carcinoma AD 155240
Fanconi Anemia, Complementation Group C AR 227645
Fanconi Anemia, Complementation Group J AR 609054
Fanconi Anemia, Complementation Group N AR 610832
Fanconi Anemia, Complementation Group O AR 613390
Fanconi Anemia, Complementation Group U AR 617247
Fumarase Deficiency AR 606812
Gastrointestinal Stromal Tumors AD 606764
Glioma Susceptibility 9 AD 616568
Goiter, Multinodular 1, With Or Without Sertoli-Leydig Cell Tumors AD 138800
Gorlin Syndrome AD 109400
Hereditary Diffuse Gastric Cancer AD 137215
Hereditary Leiomyomatosis And Renal Cell Cancer AD 150800
Hereditary Mixed Polyposis Syndrome 2 AD 610069
Hereditary Nonpolyposis Colorectal Cancer Type 4 AD 614337
Hereditary Nonpolyposis Colorectal Cancer Type 5 AD 614350
Hereditary Nonpolyposis Colorectal Cancer Type 7 AD 614385
Hereditary Nonpolyposis Colorectal Cancer Type 8 AD 613244
Hyperparathyroidism 1 AD 145000
Hyperparathyroidism 2 AD 145001
Juvenile Polyposis Syndrome AD 174900
Juvenile Polyposis/Hereditary Hemorrhagic Telangiectasia Syndrome AD 175050
Li-Fraumeni Syndrome AD 151623
Lynch Syndrome I AD 120435
Lynch Syndrome II AD 609310
Medulloblastoma AD 155255
Melanoma Astrocytoma Syndrome AD 155755
Melanoma, Cutaneous Malignant 2 AD 155601
Melanoma, Cutaneous Malignant 3 AD 609048
Melanoma, cutaneous malignant, susceptibility to, 8 AD 614456
Melanoma-Pancreatic Cancer Syndrome AD 606719
Meningioma, Familial AD 607174
Multiple Endocrine Neoplasia, Type 1 AD 131100
Multiple Endocrine Neoplasia, Type 2A AD 171400
Multiple Endocrine Neoplasia, Type 2B AD 162300
Multiple Endocrine Neoplasia, Type IV AD 610755
Myeloproliferative/Lymphoproliferative Neoplasms, Familial (Multiple Types), Susceptibility to AD 616871
Myh-Associated Polyposis AR 608456
Neuroblastoma 1 AD 256700
Neuroblastoma 2 AD 613013
Neuroblastoma 3 AD 613014
Neurofibromatosis, Type 1 AD 162200
Neurofibromatosis, Type 2 AD 101000
Nijmegen Breakage Syndrome AR 251260
Nijmegen Breakage Syndrome-Like Disorder AR 613078
Noonan Syndrome 10 AD 616564
Oligodontia-Colorectal Cancer Syndrome AD 608615
Pancreatic Cancer 1 AD 606856
Pancreatic Cancer 2 AD 613347
Pancreatic Cancer 3 AD 613348
Pancreatic Cancer 4 AD 614320
Paraganglioma And Gastric Stromal Sarcoma AD 606864
Paragangliomas 2 AD 601650
Paragangliomas 3 AD 605373
Paragangliomas 4 AD 115310
Paragangliomas 5 AD 614165
Parathyroid Carcinoma AD 608266
Perlman Syndrome AR 267000
Peutz-Jeghers Syndrome AD 175200
Pheochromocytoma AD 171300
Pigmented Nodular Adrenocortical Disease, Primary, 1 AD 610489
Pituitary Adenoma, Growth Hormone-Secreting AD 102200
Pleuropulmonary Blastoma AD 601200
Pneumothorax, Primary Spontaneous AD 173600
Primary Macronodular Adrenal Hyperplasia AD 615954
Prostate Cancer AD 176807
Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 1; PFBMFT1 AD 614742
Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 2 AD 614743
Renal Cell Carcinoma, Papillary, 1 AD 605074
Retinoblastoma AD 180200
Rhabdoid Tumor Predisposition Syndrome 1 AD 609322
Rhabdoid Tumor Predisposition Syndrome 2 AD 613325
Schwannomatosis 1 AD 162091
Schwannomatosis 2 AD 615670
Simpson-Golabi-Behmel Syndrome AD 312870
Thrombocytopenia 2 AD 188000
Thrombocytopenia 5 AD 616216
Thrombocytopenia, Familial, With Propensity To Acute Myelogenous Leukemia AD 601399
Tuberous Sclerosis 1 AD 191100
Tuberous Sclerosis 2 AD 613254
Tumor Predisposition Syndrome AD 614327
Wilms Tumor 6, Susceptibility to AD 616806
Wilms' Tumor AD 194070

Related Test

Name
PGxome®

Citations

  • Antoniou et al. 2014. PubMed ID: 25099575
  • Bartsch et al. 2012. PubMed ID: 22664588
  • Carneiro et al. 2007. PubMed ID: 17513507
  • Castéra et al. 2014. PubMed ID: 24549055
  • Chubb et al. 2015. PubMed ID: 25559809
  • Eng. 2003. PubMed ID: 12938083
  • Foulkes. 2008. PubMed ID: 19005198
  • Goldstein et al. 2006. PubMed ID: 17047042
  • Hermel et al. 2017. PubMed ID: 27401692
  • Ibrahim et al. 2009. PubMed ID: 19400696
  • Imyanitov and Byrski. 2013. PubMed ID: 23548133
  • Jasperson et al. 2017. PubMed ID: 20301519
  • Kastrinos et al. 2009. PubMed ID: 19861671
  • Kaurah and Huntsman. 2014. PubMed ID: 20301318
  • Kohlmann and Gruber. 2018. PubMed ID: 20301390
  • Laken et al. 1999. PubMed ID: 10051640
  • Larsen Haidle and Howe. 2017. PubMed ID: 20301642
  • Lindor et al. 2008. PubMed ID: 18559331
  • Marquard and Eng. 2015. PubMed ID: 20301434
  • Mauer et al. 2014. PubMed ID: 24113346
  • McGarrity et al. 2016. PubMed ID: 20301443
  • Melham-Bertrandt et al. 2012. PubMed ID: 21761402
  • Nelson and Tsao. 2009. PubMed ID: 19095153
  • O'Daniel and Lee. 2012. PubMed ID: 22846728
  • Peltomaki and Vasen 2004. PubMed ID: 15528792
  • Petrucelli et al. 2016. PubMed ID: 20301425
  • Pritchard et al. 2016. PubMed ID: 27433846
  • Sampson et al. 2003. PubMed ID: 12853198
  • Schneider et al. 2013. PubMed ID: 20301488
  • Solomon et al. 2012. PubMed ID: 23187834
  • Susswein. 2016. PubMed ID: 26681312
  • Syngal et al. 2000. PubMed ID: 10978352
  • Vuorela et al. 2011. PubMed ID: 21750962
  • Walsh et al. 2011. PubMed ID: 22006311
  • Welander et al. 2011. PubMed ID: 22041710
  • Wimmer and Etzler. 2008. PubMed ID: 18709565
  • Zhen et al. 2015. PubMed ID: 25356972

Ordering/Specimens

Ordering Options

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

Specimen Types

loading Loading... ×

Copy Text to Clipboard
×